Literature DB >> 23479004

Identification of steroid sensitive responders versus non-responders in the treatment of keloid disease.

Sara Ud-Din1, Alison Bowring, Barbara Derbyshire, Julie Morris, Ardeshir Bayat.   

Abstract

Intralesional corticosteroid injection is a well-recognised treatment modality for keloid disease (KD). Approximately 50% of KD cases are considered non-responders (or steroid resistant) with no consensus or indicators in detecting steroid-sensitive cases. In view of the undesirable side effects, uncertainty in timing and regularity of steroid treatment, we planned to identify responders and non-responders to target treatment more effectively. A scar injection proforma was developed capturing a detailed history focusing on symptoms and signs (redness, appearance, contour, texture, distortion and severity) associated with KD. The cause, site, number of keloid scars and scar recurrence were recorded as the lesions were injected on a monthly basis. A detailed description of response to steroid injection was documented and photographs were taken. Demographic data were collected on 65 patients (11 to 74 years with mean age 34.7 years, 60% were females, 50% were Caucasian). 77% (n = 50) were classified as steroid responders and showed improvement in symptoms and signs within 3 months. There was a statistically significant correlation between patients with higher contour scores of KD prior to treatment (p = 0.013) and frequency of injections (p = 0.003). Thus, the odds of being a responder were greater for patients with more than one injection and with higher contour scores. This preliminary case series has provided early evidence in enabling identification of steroid responders versus non-responders within a 3-month period. Selection of KD non-responders to steroid treatment can avoid potentially painful injection, its subsequent side effects and unnecessary continuation of redundant therapy and follow-up.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23479004     DOI: 10.1007/s00403-013-1328-7

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  6 in total

1.  Non-invasive evaluation of therapeutic response in keloid scar using diffuse reflectance spectroscopy.

Authors:  Chao-Kai Hsu; Shih-Yu Tzeng; Chao-Chun Yang; Julia Yu-Yun Lee; Lynn Ling-Huei Huang; Wan-Rung Chen; Michael Hughes; Yu-Wen Chen; Yu-Kai Liao; Sheng-Hao Tseng
Journal:  Biomed Opt Express       Date:  2015-01-08       Impact factor: 3.732

Review 2.  Controlling Inflammation Pre-Emptively or at the Time of Cutaneous Injury Optimises Outcome of Skin Scarring.

Authors:  Sara Ud-Din; Ardeshir Bayat
Journal:  Front Immunol       Date:  2022-05-27       Impact factor: 8.786

Review 3.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

4.  Keloid treatment: what about adjuvant radiotherapy?

Authors:  Ilias G Petrou; Kheeldass Jugun; Eva Meia Rüegg; Thomas Zilli; Ali Modarressi; Brigitte Pittet-Cuénod
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-05-03

Review 5.  Understanding Keloid Pathobiology From a Quasi-Neoplastic Perspective: Less of a Scar and More of a Chronic Inflammatory Disease With Cancer-Like Tendencies.

Authors:  Silvian Tan; Nonhlanhla Khumalo; Ardeshir Bayat
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

6.  Non-Invasive and Surgical Modalities for Scar Management: A Clinical Algorithm.

Authors:  Khaled Dastagir; Doha Obed; Florian Bucher; Thurid Hofmann; Katharina I Koyro; Peter M Vogt
Journal:  J Pers Med       Date:  2021-11-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.